Zi Bo Dong
Corporate Officer/Principal bei Jumpcan Pharmaceutical Co. Ltd.
Profil
Zi Bo Dong is currently the Deputy GM & Head of Drug Research Institute at Jumpcan Pharmaceutical Co. Ltd.
Prior to this, he worked as the Director & Deputy General Manager at Hubei Jumpcan Pharmaceutical Co., Ltd.
Aktive Positionen von Zi Bo Dong
| Unternehmen | Position | Beginn |
|---|---|---|
Jumpcan Pharmaceutical Co. Ltd.
 Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Zi Bo Dong
| Unternehmen | Position | Ende |
|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Direktor/Vorstandsmitglied | 28.07.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Jumpcan Pharmaceutical Co. Ltd.
Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Health Technology |